Abstract
Further to the wellestablished association between apolipoprotein E (APOE) and Alzheimer’s disease, this gene has also been implicated in both susceptibility to, and dementia in, Parkinson’s disease (PD). However studies to date have produced contradictory findings. We conducted a case-control study in a population of 528 PD patients and 512 healthy controls and found no significant difference in allele or genotype distribution of APOE between the two groups. An updated meta-analysis showed a modest increase of APOE-ε2 carriers amongst PD patients compared to controls [P = 0.017, OR = 1.16 (95 % CI 1.03–1.31)]. 107 of our patients were incident cases participating in a populationbased epidemiological study. Longitudinal follow-up of this cohort over a mean of 5.0 ± 0.7 years from diagnosis revealed no significant impact of APOE-ε4 carrier status on risk of dementia or rate of cognitive decline. An updated meta-analysis indicated an over-representation of APOE-ε4 carriers amongst PD dementia compared to non dementia cases [OR 1.74 (1.36–2.23), P = 1 × 10–4], although small sample sizes, heterogeneity of odds ratios and publication bias may have confounded this finding. In conclusion, our study does not support previously reported associations between APOE genotype and susceptibility to, or cognitive decline in, PD. An updated meta-analysis indicates any association with PD susceptibility is at most modest, an observation with important implications for further study of this issue. Large scale longitudinal studies would be best placed to further evaluate any impact of APOE genotype on cognitive decline in PD.
Similar content being viewed by others
References
Blazquez L, Otaegui D, Saenz A, Paisan-Ruiz C, Emparanza JI, Ruiz- Martinez J, Moreno F, Marti-Masso JF, Lopez de Munain A (2006) Apolipoprotein E epsilon4 allele in familial and sporadic Parkinson’s disease. Neurosci Lett 406:235–239
Bon MA, Jansen Steur EN, de Vos RA, Vermes I (1999) Neurogenetic correlates of Parkinson’s disease: apolipoprotein- E and cytochrome P450 2D6 genetic polymorphism. Neurosci Lett 266:149–151
Buchanan DD, Silburn PA, Prince JA, Mellick GD (2007) Association of APOE with Parkinson disease age-atonset in women. Neurosci Lett 411:185–188
Camicioli R, Rajput A, Rajput M, Reece C, Payami H, Hao C (2005) Apolipoprotein E epsilon4 and catechol-Omethyltransferase alleles in autopsyproven Parkinson’s disease: relationship to dementia and hallucinations. Mov Disord 20:989–994
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak- Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261:921–923
Dudbridge F (2003) Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 25:115–121
Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278:1349–1356
Feldman B, Chapman J, Korczyn AD (2006) Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson’s disease. Acta Neurol Scand 113:14–17
Foltynie T, Brayne CE, Robbins TW, Barker RA (2004) The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study. Brain 127:550–560
Foltynie T, Sawcer S, Brayne C, Barker RA (2002) The genetic basis of Parkinson’s disease. J Neurol Neurosurg Psychiatry 73:363–370
Fung HC, Scholz S, Matarin M, Simon- Sanchez J, Hernandez D, Britton A, Gibbs JR, Langefeld C, Stiegert ML, Schymick J, Okun MS, Mandel RJ, Fernandez HH, Foote KD, Rodriguez RL, Peckham E, De Vrieze FW, Gwinn- Hardy K, Hardy JA, Singleton A (2006) Genome-wide genotyping in Parkinson’s disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol 5:911–916
Gallardo G, Schluter OM, Sudhof TC (2008) A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. Nat Neurosci 11:301–308
Ghebremedhin E, Del Tredici K, Vuksic M, Rub U, Thal DR, Burbach GJ, Rosenberger A, Bickeboller H, Deller T, de Vos RA, Jansen Steur EN, Braak H (2006) Relationship of apolipoprotein E and age at onset to Parkinson disease neuropathology. J Neuropathol Exp Neurol 65:116–123
Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJ, Brown J, Ban M, Spillantini MG, Compston A, Burn DJ, Chinnery PF, Barker RA, Sawcer SJ (2007) Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson’s disease. Ann Neurol 62:145–153
Higuchi S, Matsushita S, Nakane J, Arai H, Matsui T, Urakami K, Yuzuriha T, Takeda A (2000) Alpha2-macroglobulin gene polymorphisms show racial diversity and are not associated with Alzheimer’s disease. Neuroreport 11:1167–1171
Huang X, Chen P, Kaufer DI, Troster AI, Poole C (2006) Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch Neurol 63:189–193
Huang X, Chen PC, Poole C (2004) APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology 62:2198–2202
Jasinska-Myga B, Opala G, Goetz CG, Tustanowski J, Ochudlo S, Gorzkowska A, Tyrpa J (2007) Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. Arch Neurol 64:261–265
Klein C, Lohmann-Hedrich K (2007) Impact of recent genetic findings in Parkinson’s disease. Curr Opin Neurol 20:453–464
Lopez M, Guerrero J, Yescas P, Boll MC, Familiar I, Ochoa A, Rasmussen A, Alonso ME (2007) Apolipoprotein E epsilon4 allele is associated with Parkinson disease risk in a Mexican Mestizo population. Mov Disord 22:417–420
Maraganore DM, de Andrade M, Lesnick TG, Strain KJ, Farrer MJ, Rocca WA, Pant PV, Frazer KA, Cox DR, Ballinger DG (2005) High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet 77:685–693
Maraganore DM, Farrer MJ, Hardy JA, McDonnell SK, Schaid DJ, Rocca WA (2000) Case-control study of debrisoquine 4-hydroxylase, N-acetyltransferase 2, and apolipoprotein E gene polymorphisms in Parkinson’s disease. Mov Disord 15:714–719
Pankratz N, Byder L, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T, Nichols WC (2006) Presence of an APOE4 allele results in significantly earlier onset of Parkinson’s disease and a higher risk with dementia. Mov Disord 21:45–49
Papapetropoulos S, Farrer MJ, Stone JT, Milkovic NM, Ross OA, Calvo L, McQuorquodale D, Mash DC (2007) Phenotypic associations of tau and ApoE in Parkinson’s disease. Neurosci Lett 414:141–144
Porter B, Macfarlane R, Unwin N, Walker R (2006) The prevalence of Parkinson’s disease in an area of North Tyneside in the North-East of England. Neuroepidemiology 26:156–161
Troster AI, Fields JA, Paolo AM, Koller WC (2006) Absence of the apolipoprotein E epsilon4 allele is associated with working memory impairment in Parkinson’s disease. J Neurol Sci 248:62–67
Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 130:1787–1798
Williams-Gray CH, Goris A, Foltynie T, Brown J, Maranian M, Walton A, Compston DA, Sawcer SJ, Barker RA (2006) Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson’s disease cohort. J Neurol Neurosurg Psychiatry 77:665–667
Author information
Authors and Affiliations
Corresponding author
Additional information
These authors contributed equally to this work and should be regarded as joint first authors.
These authors contributed equally to this work and should be regarded as joint senior authors.
Rights and permissions
About this article
Cite this article
Williams-Gray, C.H., Goris, A., Saiki, M. et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s Disease. J Neurol 256, 493–498 (2009). https://doi.org/10.1007/s00415-009-0119-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-009-0119-8